Navigation Links
HIV accessory protein disables host immunity via receptor-protein intermediary

Researchers at the University of Pennsylvania School of Medicine discovered that an HIV-1 accessory protein called Vpr destroys the host cell's ability to survive by binding to a host receptor. This, in turn, keeps an important enzyme from activating the cell's immune system. These findings refine an earlier understanding of Vpr HIV pathogenesis and imply new approaches to treating AIDS, inflammatory diseases such as rheumatoid arthritis, and possibly sepsis. This research appears in the February print issue of Nature Cell Biology.

Over a decade ago, Penn's David Weiner, PhD, Associate Professor of Pathology and Laboratory Medicine, and colleagues reported that Vpr corrupted the glucocorticoid receptor (GR) pathway of the host cell. Vpr helps to usurp host-cell function by regulating cell differentiation, cell death, and suppressing host-cell immune response proteins. Weiner's group found that Vpr binds to the glucocorticoid receptor, but it remained unclear whether the GR pathway was required for Vpr to commandeer the host cell's machinery.

"We started to realize a few years ago that no one had asked the real question: Is the glucocorticoid receptor necessary for Vpr's effects on the host cell?" recalls Weiner. To answer this question, the researchers used an siRNA, a short sequence of RNA used to silence gene expression, to completely destroy expression of the glucocorticoid receptor protein.

When the researchers kept the glucocorticoid receptor protein from being made, Vpr did not kill host cells. "This indicated that glucocorticoid receptor function is not what's really necessary for Vpr activity," says Weiner. "The glucocorticoid receptor-Vpr complex must be interacting with something else."

The team, led by first author Muthumani Karuppiah, PhD, Senior Research Investigator, looked for molecules with which the glucocorticoid receptor-Vpr complex would bind and identified PARP-1, another protein that controls the action of NF-
'"/>

Source:University of Pennsylvania School of Medicine


Page: 1 2

Related biology news :

1. New, automated tool successfully classifies and relates proteins in unprecedented way
2. New binding target for oncogenic viral protein
3. Controversial drug shown to act on brain protein to cut alcohol use
4. Timing is everything: First step in protein building revealed
5. UWs Rosetta software to unlock secrets of many human proteins
6. Researchers find how protein allows insects to detect and respond to pheromones
7. Signaling protein builds bigger, better bones in mice
8. Ancient olfaction protein is shared by many bugs, offering new pest control target
9. Automatic extraction of gene/protein biological functions from biomedical text
10. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
11. Scientists develop new color-coded test for protein folding
Post Your Comments:
(Date:7/11/2014)... Society for Bone and Mineral Research awarded Michael F. ... (BUSM), with the 2014 Louis V. Avioli Award. Holick, ... is internationally known for revolutionizing the understanding of vitamin ... The award honors a member of the American Society ... to bone and mineral basic research. It is named ...
(Date:7/11/2014)... . X-ray ... of X-rays through a specimen instead of attenuation resulting ... often of much higher quality than those based on ... Pfeiffer are particularly interested in developing new approaches for ... imaging. One main goal is to make this method ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2New simple setup for X-ray phase contrast 2
... a future when man and machine would become one. ... futuristic "vision" of bionics a reality. Prof. Yael ... has foundational research that may give sight to blind ... growth. Successful so far in animal models, this research ...
... Calif., March 19, 2010Under a changing climate, patterns ... how will forest diseases respond? A summary of ... available on the Internet at http://www.fs.fed.us/psw/topics/insect_disease/ . ... titled "Review of Literature on Climate Change and ...
... big jobs in our environment, to go dormant not only ... also play a key role in promoting biodiversity and ecosystem ... Proceedings of National Academy of Sciences , Michigan State ... a mathematical model and molecular tools to study how dormancy ...
Cached Biology News:Seeing a bionic eye on medicine's horizon 2How will tree diseases react to climate change? 2Dormant microbes promote diversity, serve environment 2
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... San Francisco, CA (PRWEB) July 10, 2014 ... a family closer together. The Archer Family purchased ... information contained within DNA, but ended up with a ... surprising discoveries contained within the family members’ DNA genuinely ... family had decided to search deeper into genetic history ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... , , , BALTIMORE, ... (OTC Bulletin Board: CSBR), a company engaged in the development ... the value of oncology drugs, has established yet another agreement ... novel oncology therapeutic in Champions, Biomerk Tumorgraft(TM) platform. , ...
... , , ROCKVILLE, Md., ... today favorable results from a Phase II human clinical trial of ... vaccine was well tolerated and induced robust immune responses against all ... support the planned study in elderly adults scheduled for the fourth ...
... COPENHAGEN and OSLO, September 1 Affitech ... announced that it,has appointed two experienced biotech executives ... CEO of Celldex Therapeutics Inc., has today,assumed overall ... Dr Alexander Duncan, previously SVP Biopharmaceuticals for Astra,Zeneca ...
Cached Biology Technology:Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 2Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 4NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate 5Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3
... standard fixed-angle microcentrifuge rotor at RCF ... tube filters consist of a membrane-containing ... They filter by centrifugation for bacteria ... removal of cells from media and ...
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
... System provides high-throughput, quantitative gene expression analysis ... patented priming strategy overcomes the biases that ... a few genes at a time. ... and more samples per run, removing bottlenecks ...
... provides a convenient method to probe conformational changes ... substrates. Thus, the kit may be used to ... as transport substrates for MDR1. Because UIC2 binding ... substrates, the MDR1 Shift Assay can be utilized ...
Biology Products: